Unknown

Dataset Information

0

Landiolol suppression of electrical storm of torsades de pointes in patients with congenital long-QT syndrome type 2 and myocardial ischemia.

ABSTRACT: A 76-year-old man who had been diagnosed with long-QT syndrome type 2 had frequent syncopal attacks. The electrocardiogram was monitored, and frequent torsades de pointes (TdP) was detected despite administration of conventional medications: oral propranolol, verapamil, intravenous magnesium sulfate, verapamil, and lidocaine. In contrast, 2 ?g/kg/min landiolol could completely suppress TdP. Subsequently, an implantable cardioverter defibrillator was placed, and he was diagnosed with silent myocardial ischemia using myocardial perfusion scintigraphy and coronary angiography. This is the first case report wherein landiolol effectively suppressed TdP due to long-QT syndrome with silent myocardial ischemia.

SUBMITTER: Kitajima R 

PROVIDER: S-EPMC5634675 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Landiolol suppression of electrical storm of torsades de pointes in patients with congenital long-QT syndrome type 2 and myocardial ischemia.

Kitajima Ryota R   Aiba Takeshi T   Kamakura Tsukasa T   Ishibashi Kohei K   Wada Mitsuru M   Inoue Yuko Y   Miyamoto Koji K   Okamura Hideo H   Noda Takashi T   Nagase Satoshi S   Kataoka Yu Y   Asaumi Yasuhide Y   Noguchi Teruo T   Yasuda Satoshi S   Kusano Kengo K  

Journal of arrhythmia 20170627 5

A 76-year-old man who had been diagnosed with long-QT syndrome type 2 had frequent syncopal attacks. The electrocardiogram was monitored, and frequent torsades de pointes (TdP) was detected despite administration of conventional medications: oral propranolol, verapamil, intravenous magnesium sulfate, verapamil, and lidocaine. In contrast, 2 μg/kg/min landiolol could completely suppress TdP. Subsequently, an implantable cardioverter defibrillator was placed, and he was diagnosed with silent myoca  ...[more]

Similar Datasets

Unknown Drug induced QT prolongation and torsades de pointes.
| S-EPMC1767957 | biostudies-literature
Unknown Global electrical heterogeneity associated with drug-induced torsades de pointes.
| S-EPMC7796973 | biostudies-literature
Unknown Electrical organization of torsades de pointes into monomorphic ventricular tachycardia.
| S-EPMC7793232 | biostudies-literature
Unknown PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
| S-EPMC7047052 | biostudies-literature
Unknown Mechanisms of fever-induced QT prolongation and torsades de pointes in patients with KCNH2 mutation.
| S-EPMC10310978 | biostudies-literature
Unknown Successful Management of Fetal Torsades de Pointes and Long QT Syndrome by a Cardio-Obstetrical Team.
| S-EPMC10715977 | biostudies-literature
Unknown Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.
| S-EPMC3335957 | biostudies-literature
Unknown Electrical storm in an infant with short-coupled variant of torsade de pointes.
| S-EPMC6009772 | biostudies-literature
Unknown Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
| S-EPMC7166303 | biostudies-literature
Unknown Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.
| S-EPMC3422407 | biostudies-literature